Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 5.07
ACRX's Cash to Debt is ranked higher than
56% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. ACRX: 5.07 )
Ranked among companies with meaningful Cash to Debt only.
ACRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.31  Med: 3.61 Max: N/A
Current: 5.07
Equity to Asset 0.19
ACRX's Equity to Asset is ranked lower than
91% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. ACRX: 0.19 )
Ranked among companies with meaningful Equity to Asset only.
ACRX' s Equity to Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.53 Max: 0.69
Current: 0.19
-0.01
0.69
F-Score: 5
Z-Score: -0.91
M-Score: 0.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -77.24
ACRX's Operating margin (%) is ranked lower than
75% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. ACRX: -77.24 )
Ranked among companies with meaningful Operating margin (%) only.
ACRX' s Operating margin (%) Range Over the Past 10 Years
Min: -1805.22  Med: -721.66 Max: -22.6
Current: -77.24
-1805.22
-22.6
Net-margin (%) -114.69
ACRX's Net-margin (%) is ranked lower than
79% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.77 vs. ACRX: -114.69 )
Ranked among companies with meaningful Net-margin (%) only.
ACRX' s Net-margin (%) Range Over the Past 10 Years
Min: -1875.09  Med: -639.31 Max: -79.4
Current: -114.69
-1875.09
-79.4
ROE (%) -74.14
ACRX's ROE (%) is ranked lower than
86% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 0.98 vs. ACRX: -74.14 )
Ranked among companies with meaningful ROE (%) only.
ACRX' s ROE (%) Range Over the Past 10 Years
Min: -130.03  Med: -58.42 Max: -43.78
Current: -74.14
-130.03
-43.78
ROA (%) -24.39
ACRX's ROA (%) is ranked lower than
69% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. ACRX: -24.39 )
Ranked among companies with meaningful ROA (%) only.
ACRX' s ROA (%) Range Over the Past 10 Years
Min: -134.55  Med: -73.84 Max: -22.78
Current: -24.39
-134.55
-22.78
ROC (Joel Greenblatt) (%) -154.24
ACRX's ROC (Joel Greenblatt) (%) is ranked lower than
73% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. ACRX: -154.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1434.7  Med: -948.27 Max: -197.89
Current: -154.24
-1434.7
-197.89
Revenue Growth (3Y)(%) 58.90
ACRX's Revenue Growth (3Y)(%) is ranked higher than
98% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. ACRX: 58.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 58.9
Current: 58.9
0
58.9
EBITDA Growth (3Y)(%) -35.80
ACRX's EBITDA Growth (3Y)(%) is ranked lower than
92% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ACRX: -35.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -35.80 Max: -14.7
Current: -35.8
EPS Growth (3Y)(%) -28.50
ACRX's EPS Growth (3Y)(%) is ranked lower than
87% of the 202 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. ACRX: -28.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -28.50 Max: -12.8
Current: -28.5
» ACRX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2014

ACRX Guru Trades in Q4 2014

Paul Tudor Jones Sold Out
» More
Q1 2015

ACRX Guru Trades in Q1 2015

Paul Tudor Jones 52,600 sh (New)
» More
Q2 2015

ACRX Guru Trades in Q2 2015

Paul Tudor Jones 24,100 sh (-54.18%)
» More
Q3 2015

ACRX Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:XKRX:054950, ASX:IPD, NAS:RTIX, OTCPK:VICA, NAS:TNDM, NAS:IRMD » details
Traded in other countries:R5X.Germany,
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of therapies for the treatment of acute pain.

AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialty pharmaceutical company engaged in the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company's main product candidate, Zalviso, formerly known as the Sufentanil NanoTab PCA System, or ARX-01, is currently under review by the FDA for marketing approval, and is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal for the commercialization of Zalviso in Europe and Australia. Its sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Its registered trademarks include ACELRX and NANOTAB.

Ratios

vs
industry
vs
history
P/B 6.75
ACRX's P/B is ranked lower than
81% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.69 vs. ACRX: 6.75 )
Ranked among companies with meaningful P/B only.
ACRX' s P/B Range Over the Past 10 Years
Min: 2.13  Med: 6.00 Max: 77.52
Current: 6.75
2.13
77.52
P/S 7.08
ACRX's P/S is ranked lower than
75% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. ACRX: 7.08 )
Ranked among companies with meaningful P/S only.
ACRX' s P/S Range Over the Past 10 Years
Min: 6.27  Med: 38.21 Max: 2370
Current: 7.08
6.27
2370
Current Ratio 6.71
ACRX's Current Ratio is ranked higher than
85% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ACRX: 6.71 )
Ranked among companies with meaningful Current Ratio only.
ACRX' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 5.21 Max: 20.39
Current: 6.71
0.43
20.39
Quick Ratio 6.66
ACRX's Quick Ratio is ranked higher than
87% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. ACRX: 6.66 )
Ranked among companies with meaningful Quick Ratio only.
ACRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 5.21 Max: 20.39
Current: 6.66
0.43
20.39
Days Inventory 18.71
ACRX's Days Inventory is ranked higher than
95% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 136.13 vs. ACRX: 18.71 )
Ranked among companies with meaningful Days Inventory only.
ACRX' s Days Inventory Range Over the Past 10 Years
Min: 48.05  Med: 48.05 Max: 48.05
Current: 18.71
Days Sales Outstanding 52.93
ACRX's Days Sales Outstanding is ranked higher than
73% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 69.05 vs. ACRX: 52.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.26  Med: 62.26 Max: 62.26
Current: 52.93
Days Payable 244.74
ACRX's Days Payable is ranked higher than
91% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 62.25 vs. ACRX: 244.74 )
Ranked among companies with meaningful Days Payable only.
ACRX' s Days Payable Range Over the Past 10 Years
Min: 321.9  Med: 321.90 Max: 321.9
Current: 244.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.57
ACRX's Price/Net Cash is ranked lower than
51% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 15.00 vs. ACRX: 16.57 )
Ranked among companies with meaningful Price/Net Cash only.
ACRX' s Price/Net Cash Range Over the Past 10 Years
Min: 2.2  Med: 9.02 Max: 25
Current: 16.57
2.2
25
Price/Net Current Asset Value 10.55
ACRX's Price/Net Current Asset Value is ranked lower than
71% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: 6.66 vs. ACRX: 10.55 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.14  Med: 7.60 Max: 927
Current: 10.55
2.14
927
Price/Tangible Book 6.69
ACRX's Price/Tangible Book is ranked lower than
71% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. ACRX: 6.69 )
Ranked among companies with meaningful Price/Tangible Book only.
ACRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.08  Med: 5.80 Max: 57.58
Current: 6.69
2.08
57.58
Price/Median PS Value 0.19
ACRX's Price/Median PS Value is ranked higher than
96% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. ACRX: 0.19 )
Ranked among companies with meaningful Price/Median PS Value only.
ACRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.16  Med: 0.93 Max: 57.38
Current: 0.19
0.16
57.38
Earnings Yield (Greenblatt) (%) -23.86
ACRX's Earnings Yield (Greenblatt) (%) is ranked lower than
86% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. ACRX: -23.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -26.77  Med: 3.75 Max: 9.1
Current: -23.86
-26.77
9.1

More Statistics

Revenue (TTM) (Mil) $22.11
EPS (TTM) $ -0.58
Beta2.90
Short Percentage of Float12.90%
52-Week Range $2.59 - 5.88
Shares Outstanding (Mil)45.31

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 12 7 41
EPS ($) -0.92 -1.01 -0.46
EPS without NRI ($) -0.92 -1.01 -0.46
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for ACRX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Other Websites
7:08 am AcelRx will present Phase 3 SAP301 study results at Euroanaesthesia 2016 at 12:15 on May 30;... May 26 2016
AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 following Ambulatory... May 26 2016
New Study Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of... May 24 2016
ETF’s with exposure to AcelRx Pharmaceuticals, Inc. : May 19, 2016 May 19 2016
AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
ACELRX PHARMACEUTICALS INC Financials May 07 2016
AcelRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX‑04 by Type... May 06 2016
AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in May May 04 2016
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 04 2016
Edited Transcript of ACRX earnings conference call or presentation 2-May-16 8:30pm GMT May 03 2016
ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 02 2016
AcelRx Pharmaceuticals reports 1Q loss May 02 2016
AcelRx Pharmaceuticals reports 1Q loss May 02 2016
AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today May 02 2016
AcelRx Pharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results May 02 2016
Q1 2016 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close May 02 2016
AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on... Apr 28 2016
AcelRx Pharmaceuticals (ACRX): Strong Industry, Solid Earnings Estimate Revisions Apr 12 2016
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 31 2016
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 30 2016
AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on... Mar 29 2016
AcelRx Publishes a Review of Hospital-Based Opioid Patient-Controlled Analgesia, Risks and... Mar 25 2016
ETF’s with exposure to AcelRx Pharmaceuticals, Inc. : March 24, 2016 Mar 24 2016
AcelRx Pharmaceuticals reports 4Q loss Mar 07 2016
AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet... Jan 21 2016
AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones Jan 10 2016
AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312)... Jan 08 2016
AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review of ARX-04 from European... Dec 23 2015
AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04 Dec 14 2015
AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of... Nov 19 2015
AcelRx Pharmaceuticals tops Street 3Q forecasts Oct 29 2015
AcelRx Pharmaceuticals Provides Business Update and Reports Third Quarter and Nine Months 2015... Oct 29 2015
AcelRx Pharmaceuticals to Hold Business Update and Third Quarter Financial Results Conference Call... Oct 26 2015
AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30... Oct 23 2015
AcelRX Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30mcg Tablet Data At... Oct 09 2015
AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso Oct 08 2015
AcelRx Pharmaceuticals Announces Initiation of Clinical Study with ARX-04 in Emergency Room Patients... Oct 06 2015
AcelRx Pharmaceuticals Appoints Gina Ford as Vice President Commercial Strategy Oct 01 2015
AcelRx Pharmaceuticals to Host Analyst & Investor Event on October 2, 2015 Sep 24 2015
PDL BioPharma Acquires a Portion of AcelRx Pharmaceuticals' Expected Royalties and Commercial... Sep 23 2015
AcelRx Pharmaceuticals Reports that the European Commission has Granted Marketing Authorization for... Sep 22 2015
AcelRx Pharmaceuticals Receives $65 Million from the Partial Sale of Zalviso™ European Royalties... Sep 21 2015
AcelRx Pharmaceuticals' ARX-04 Meets all Endpoints in Pivotal Phase 3 Study for Moderate-to-Severe... Sep 09 2015
AcelRx Pharmaceuticals to Participate at Three Investor Conferences In September Aug 26 2015
AcelRx Pharmaceuticals reports 2Q loss Aug 03 2015
AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015... Aug 03 2015
AcelRx Pharmaceuticals reports 1Q loss May 04 2015
AcelRx Pharmaceuticals posts 3Q profit Nov 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)